CeriBell, Inc./$CBLL
1D1W1MYTD1Y5YMAX
Capital at risk
About CeriBell, Inc.
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.
- Ticker
- $CBLL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 327
- Headquarters
- Sunnyvale, United States
- Website
- www.ceribell.com
CeriBell, Inc. Metrics
BasicAdvanced
$934M
-
-$1.76
-
-
Price and volume
Market cap
$934M
52-week high
$25.33
52-week low
$10.85
Average daily volume
386K
Financial strength
Current ratio
9.177
Quick ratio
8.445
Long term debt to equity
0.162
Total debt to equity
0.171
Interest coverage (TTM)
-38.57%
Profitability
EBITDA (TTM)
-68.803
Gross margin (TTM)
88.90%
Net profit margin (TTM)
-64.73%
Operating margin (TTM)
-68.62%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-23.38%
Return on equity (TTM)
-43.93%
Valuation
Price to revenue (TTM)
8.929
Price to book
7.25
Price to tangible book (TTM)
7.25
Price to free cash flow (TTM)
-16.23
Free cash flow yield (TTM)
-6.16%
Free cash flow per share (TTM)
-1.499
Growth
Revenue change (TTM)
31.70%
Earnings per share change (TTM)
-2.78%
Bulls say / Bears say
Reported Q2 2026 revenue of $28.1 million, a 33% year-over-year increase driven by new account additions and higher utilization across existing hospital accounts. (SEC / Yahoo Finance)
Received FDA 510(k) clearances in August 2026 for two AI-driven algorithms (Epileptiform Abnormality Detection and Artifact Reduction) and new recorder and headband designs, strengthening its next-generation hardware and software platform. (GlobeNewswire / SEC)
Net loss widened to $19.3 million ($0.51 per share) in Q2 2026 from $13.6 million ($0.38 per share) in Q2 2025, underscoring persistent unprofitability despite revenue gains. (SEC / EveryTicker)
Operating expenses increased 37% year-over-year to $45.9 million in Q2 2026 due to higher spending on commercial expansion, R&D, and legal activities, intensifying cash burn. (MarketBeat / SEC)
Despite $129.3 million in cash and a new $60 million credit facility, ongoing negative adjusted EBITDA of $9.8 million and high investment levels may strain liquidity and necessitate additional financing. (MarketBeat / SEC)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
Upcoming events
No upcoming events
CeriBell, Inc. News
AllArticlesVideos
Funds containing CeriBell, Inc.
Fund name | Fund size | $CBLL weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.